Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes.

Junko OyaTomoko NakagamiYukiko HasegawaYuichiro KondoAki KatamineMika ShimizuRyo KubotaRika SudaTetsuya Babazono

Published in: Diabetology international (2024)

Once-daily IDegLira had greater effects on HbA1c and a lesser increase in insulin doses than IDegAsp when patients are switched from basal insulin therapy. Moreover, the effect on HbA1c was enhanced in patients with high HbA1c levels at baseline.

Keyphrases

type diabetes
glycemic control
end stage renal disease
randomized controlled trial
systematic review
newly diagnosed
ejection fraction
peritoneal dialysis
skeletal muscle
bone marrow
patient reported outcomes
smoking cessation